Angiosarcoma of the breast (literature review and description of two clinical observations)
R. V. Orlova,
A. V. Androsova,
E. E. Topuzov,
N. P. Belyak,
S. I. Kutukova,
I. V. Avramenko,
A. K. Ivanova,
A. A. Varankina,
A. A. Korkina,
G. A. Rakhimova https://doi.org/10.18027/2224-5057-2024-012
Abstract
Breast angiosarcoma is a rare malignancy that accounts for less than 0.5% of all breast cancers. The disease is characterized by rapid growth, aggressive course, active dissemination of the process and poor response to treatment. The peculiarity of the disease lies in the complexity of diagnosing the process, since the clinical picture is not specific and often occurs under the guise of skin diseases such as eczema, atopic dermatitis, rosacea, etc. Also, the complexity of diagnosis is complemented by the lack of specific imaging methods, thanks to which it would be possible to diagnose angiosarcoma with high accuracy. The leading element of treatment is a combined approach, namely a combination of surgical excision, drug therapy and radiation. This article presents our own experience in managing a patient with angiosarcoma of the right breast, which arose 7 years after the treatment of breast carcinoma in the St. Petersburg City Clinical Oncology Center.
Supporting agencies: The article was prepared without sponsorship
About the Authors
R. V. Orlova
Saint Petersburg State University; City Clinical Oncological Dispensary
Russian Federation
Competing Interests:
Russian Federation
Orlova Rashida Vakhidovna
7-9 universitetskaya Naberezhnaya, Saint Petersburg 199034; 56 Veteranov Prospekt, Saint Petersburg 198255
Competing Interests:
The authors declare that there are no possible conflicts of interest
A. V. Androsova
City Clinical Oncological Dispensary
Russian Federation
Competing Interests:
Russian Federation
Androsova Aleksandra Valerevna
56 Veteranov Prospekt, Saint Petersburg 198255
Competing Interests:
The authors declare that there are no possible conflicts of interest
E. E. Topuzov
City Clinical Oncological Dispensary; I. I. Mechnikov North-West State Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Topuzov Eldar Eskenderovich
56 Veteranov Prospekt, Saint Petersburg 198255; 41 Kirochnaya St., Saint Petersburg 191015
Competing Interests:
The authors declare that there are no possible conflicts of interest
N. P. Belyak
Saint Petersburg State University; City Clinical Oncological Dispensary
Russian Federation
Competing Interests:
Russian Federation
Belyak Natalya Petrovna
7-9 Universitetskaya Naberezhnaya, Saint Petersburg 199034; 56 Veteranov Prospekt, Saint Petersburg 198255
Competing Interests:
The authors declare that there are no possible conflicts of interest
S. I. Kutukova
City Clinical Oncological Dispensary; Academician I. P. Pavlov First St. Petersburg State Medical University
Russian Federation
Competing Interests:
Russian Federation
Kutukova Svetlana Igorevna
56 Veteranov Prospekt, Saint Petersburg 198255; 197022 Санкт-Петербург, ул. Аъеа Толстого, 6—8
Competing Interests:
The authors declare that there are no possible conflicts of interest
I. V. Avramenko
City Clinical Oncological Dispensary
Russian Federation
Competing Interests:
Russian Federation
56 Veteranov Prospekt, Saint Petersburg 198255
Competing Interests:
The authors declare that there are no possible conflicts of interest
A. K. Ivanova
City Clinical Oncological Dispensary
Russian Federation
Competing Interests:
Russian Federation
Ivanova Anastasiya Konstantinovna
56 Veteranov Prospekt, Saint Petersburg 198255
Competing Interests:
The authors declare that there are no possible conflicts of interest
A. A. Varankina
City Clinical Oncological Dispensary
Russian Federation
Competing Interests:
Russian Federation
56 Veteranov Prospekt, Saint Petersburg 198255
Competing Interests:
The authors declare that there are no possible conflicts of interest
A. A. Korkina
City Clinical Oncological Dispensary
Russian Federation
Competing Interests:
Russian Federation
56 Veteranov Prospekt, Saint Petersburg 198255
Competing Interests:
The authors declare that there are no possible conflicts of interest
G. A. Rakhimova
Academician I. P. Pavlov First St. Petersburg State Medical University
Russian Federation
Competing Interests:
Russian Federation
197022 Санкт-Петербург, ул. Аъеа Толстого, 6—8
Competing Interests:
The authors declare that there are no possible conflicts of interest
References
1. Virgilio E., Lombardi M., Stefano D.D., et al. Angiosarcoma of the breast: a rare and dismal complication of breast surgery associated with radiation. Am Surg 2017;83(3):e71-73
2. Farran Y., Padilla O., Chambers K., et al. Atypical presentation of radiation-associated breast angiosarcoma: a case report and review ofliterature. AmJ Case Rep 2017;18:1347-1350. https://doi.org/10.12659/ajcr.905157
3. Mergancova J., Lierova A., Coufal O., et al. Radiation-associated angiosarcoma of the breast: An international multicenter analysis. Surg Oncol 2022;41:101726. https://doi.Org/10.1016/j.suronc.2022.101726
4. Ribeiro M.F., Soroka H.P., Bhura Z., et al. Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study. Ther Adv Med Oncol 2023;15:17588359231198943. https://doi.org/10.1177/17588359231198943
5. Ryabchikov D.A., Vorotnikov I.K., Chkhikvadze N.V., et al. Breast sarcomas. Literature review. Tumors of female reproductive system. 2014;(2):12—15 (In Russ.), https://doi.org/10.17650/1994-4098-2014-0-2-12-15
6. Salminen S.H., Wiklund T., Sampo M.M., et al. Treatment and prognosis of radiation-associated breast angiosarcoma in a nationwide population. Ann Surg Oncol 2020;27(4):1002-1010. https://doi.org/10.1245/sl0434-019-08085-l
7. Shah S., Rosa M. Radiation-associated angiosarcoma of the breast: clinical and pathologic features. Arch Pathol Lab Med2016;140(5):477-481. https://doi.org/10.5858/arpa.2014-0581-RS
8. Chikarmane S.A., Combos E.C., Jagadeesan J. Et al. MRI findings of radiation-associated angiosarcoma of the breast (RAS). J Magn Reson Imaging 2015;42(3):763-770. https://doi.org/10.1002/jmri.24822
9. Cahan W.G., Woodard H.Q., Higinbotham N.L. Sarcoma arising in irradiated bone; report of 11 cases. Cancer 1948;l(l):3-29. https://doi.org/10.1002/1097-0142(194805)l:l<3::aid-cncr2820010103>3.0.co;2-7
10. Feinberg L., Srinivasan A., Singh J.K., et al. Impact of specialist management on survival from radiation-associated angiosarcoma of the breast. BrJ Surg 2018;105(4):401-409. https://doi.org/10.1002/bjs.10696
11. Dufresne A., Meeus P., Sunyach M.P. Treatment of radiation-associated angiosarcoma. Curr Opin Oncol 2023;35(4):296— 300. https://doi.org/10.1097/CCO.0000000000000958
12. Bonito F.J.P., de Almeida Cerejeira D., Dahlstedt-Ferreira C., et al. Radiation-induced angiosarcoma of the breast: Areview. BreastJ 2020;26(3):458-463. https://doi.org/10.llll/tbj.13504
13. Monroe A.T., Feigenberg S.J., Mendenhall N.P. Angiosarcoma after breast-conserving therapy. Cancer 2003;97(8):18321840. https://doi.org/10.1002/cncr.11277
14. Takehara Y., Matsuda N., Kobayashi D., et al. Radiation-induced angiosarcoma of the breast: individual participant meta-analysis ofjapanese population. Breast Cancer 2023;30(5):739-747. https://doi.org/10.1007/sl2282-023-01466-l
15. Salminen S.H., Sampo M.M., Bohling T.O., et al. Radiation-associated angiosarcoma of the breast: analysis of diagnostic tools in aregistry-basedpopulation. Acta Radiol 2022;63(l):22-27. https://doi.org/10.1177/0284185120980142
16. Suzuki Y., Taniguchi K., Hatono M., et al. Recurring radiation-induced angiosarcoma of the breast that was treated with paclitaxel chemotherapy: a case report. Surg Case Rep 2020;6(l):25. https://doi.org/10.1186/s40792-020-0790-7
17. Cohen-Hallaleh R.B., Smith H.G., Smith R.C., et al. Radiation induced angiosarcoma of the breast: outcomes from aretrospective case series. Clin Sarcoma Res 2017;7:15. https://doi.org/10.1186/sl3569-017-0081-7
18. Smith T.L., Morris C.G., Mendenhall N.P. Angiosarcoma after breastconserving therapy: long-term disease control and late effects with hyperfractionated accelerated re-irradiation (HART). Acta Oncol 2014;53(2):235-241. https://doi.org/10.3109/0284186X.2013.819117
19. Agulnik M., Yarber J.L., Okuno S.H., et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 2013;24(l):257-63. https://doi.org/10.1093/annonc/mds237
20. Ray-Coquard I.L., Domont J., Tresch-Bruneel E., et al. Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial. J Clin Oncol 2015;33(25):2797-802. https://doi.org/10.1200/JC0.2015.60.8505
21. van der Graaf W.T., Blay J.Y., Chawla S.P., et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379(9829):1879-86. https://doi.org/10.1016/S0140-6736(12)60651-5
22. Kollar A., Jones R.L., Stacchiotti S, et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol 2017;56(l):88-92. https://doi.org/10.1080/0284186X.2016.1234068
23. Woll P.J., Gaunt P., Gaskell C., et al. Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata. Br J Cancer 2023;129(9):1490-1499. https://doi.org/10.1038/s41416-023-02416-6.
Review
For citations:
Orlova R.V., Androsova A.V., Topuzov E.E., Belyak N.P., Kutukova S.I., Avramenko I.V., Ivanova A.K., Varankina A.A., Korkina A.A., Rakhimova G.A. Angiosarcoma of the breast (literature review and description of two clinical observations). Malignant tumours. 2024;14(3):49-55. (In Russ.) https://doi.org/10.18027/2224-5057-2024-012
Views:
227
Email this article 